Quality-of-life measures used routinely to assess treatment outcomes for patients with pancreatic disease may be used to predict both malignancy and survival for those patients, according to a study by Henry Ford Hospital.
Researchers found that pre-treatment quality-of-life scores could predict malignancy in patients with pancreatic lesions and survival in those who are found to have malignancies.
"Our findings suggest that pretreatment quality-of-life scores may show which patients will have a poor survival and therefore could avoid aggressive, but futile, treatment," says Vic Velanovich, M.D., chief of General Surgery at Henry Ford Hospital and lead author of the study.
Source :http://www.medicalnewstoday.com/articles/187555.php
No comments:
Post a Comment